

Section 4 Title: Identification and Classification of AMD: Making a Confident Diagnosis

Author: Vince Roberts

References

1. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. *Pharmacological reports*. 2006; 58: 353-63.
2. Kanski JJ (2006) Acquired macular disorders. In *Clinical Ophthalmology*. Fifth edition. Butterworth-Heinemann, London. Chapter 13.
3. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration. *Ophthalmology*. 2008; 115: 116-26.
4. AMD Alliance website. <http://www.amdalliance.org> [Accessed 15 January 2009]
5. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. *N Engl J Med*. 2008; 358: 2606-17.
6. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. *Ophthalmology*. 2000; 107: 2224-32.
7. Macular degeneration (age-related)- ranibizumab and pegaptanib: Final appraisal determination. 2008. Available from: <http://www.nice.org.uk/nicemedia/pdf/TA155guidance.pdf> [Accessed 15 January 2009]

8. Ranibizumab 10mg/ml solution for intravitreal injection (No. 381/07).

Available from:

http://www.scottishmedicines.org.uk/smc/files/ranibizumab_10mgmlsolution_intravitrealinjection_Lucentis_38107.pdf [Accessed 15 January 2009]

9. Pegaptanib 0.3mg solution for intravitreal injection (No. 290/06). Available from:

http://www.scottishmedicines.org.uk/smc/files/pegaptanib_Macugen_290_06.pdf [Accessed 15 January 2009]

10. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. *Retina*. 2000; 20(4): 325-30.

11. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on visual outcomes – TAP report No. 3. *Arch Ophthalmol*. 2002; 120(11): 1443-54.

12. World Health Organisation UK Statistics. Available from:

<http://www.who.int/countries/gbr/en/> [Accessed 15 January 2009]

13. Lotery A, Xu X, Zlatava G, et al. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. *Br J Ophthalmol*. 2007; 91(10):1303-7.

14. Owen CG, Fletcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol. 2003; 87: 312-7.
15. TA68 Macular degeneration (age related) - photodynamic therapy: Guidance. 2003. Available from:
http://www.nice.org.uk/nicemedia/pdf/68_PDTGuidance.pdf [Accessed 15 January 2009]
16. Lucentis SPC. Available from:
<http://www.emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=19409> [Accessed 15 January 2009]
17. Macugen SPC. Available from:
<http://www.emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=17843> [Accessed 15 January 2009]
18. General Optical Council stage 2 core competencies for optometry. Available from:
http://www.optical.org/goc/filemanager/root/site_assets/core_competencies/Optometrists.pdf [Accessed 15 January 2009]